Literature DB >> 16699031

Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes.

Nancy Hosken1, Patrick McGowan, Amalia Meier, David M Koelle, Paul Sleath, Felecia Wagener, Mark Elliott, Ken Grabstein, Christine Posavad, Lawrence Corey.   

Abstract

Cytolytic T cells play a major role in controlling herpes simplex virus type 2 (HSV-2) infections in humans. In an effort to more thoroughly evaluate the response to HSV-2 directly, ex vivo, we developed an enzyme-linked immunospot (ELISPOT) assay that utilized pools of overlapping synthetic peptides presented by autologous dendritic cells to purified CD8(+) T cells. Donor response rates to individual open reading frames (ORFs) ranged from fewer than 5% responding to as many as 70% responding, with the greatest frequency of responses (by ORF) being directed against UL39, UL25, UL27, ICP0, UL46, and UL47 in descending order of frequency. HSV-2-seropositive subjects responded to as few as 3 or as many as 46 of the 48 ORFs tested, with a median of 11 ORFs recognized. HLA-B*07 expression correlated with stronger responses overall that were directed primarily against UL49 and UL46. Cumulative precursor frequencies in the blood ranged from 500 to almost 6,000 HSV-2 spot-forming units/10(6) CD8(+) T cells. The magnitude and breadth of the response in the infected population were greater than previously appreciated. Whether this variability in the CD8(+) T-cell response within individuals is associated with the frequency of viral reactivation warrants further study.

Entities:  

Mesh:

Year:  2006        PMID: 16699031      PMCID: PMC1472180          DOI: 10.1128/JVI.02659-05

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor.

Authors:  David M Koelle; Zhi Liu; Christopher L McClurkan; Randal C Cevallos; Jeffrey Vieira; Nancy A Hosken; Clement A Meseda; Devon C Snow; Anna Wald; Lawrence Corey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

2.  CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells.

Authors:  D M Koelle; H B Chen; M A Gavin; A Wald; W W Kwok; L Corey
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

3.  T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?

Authors:  Christine M Posavad; Anna Wald; Nancy Hosken; Meei Li Huang; David M Koelle; Rhoda L Ashley; Lawrence Corey
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

4.  Herpes simplex virus type 2-specific CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles.

Authors:  David M Koelle; Hongbo B Chen; Christopher M McClurkan; Effie W Petersdorf
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

5.  Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations.

Authors:  K Cao; J Hollenbach; X Shi; W Shi; M Chopek; M A Fernández-Viña
Journal:  Hum Immunol       Date:  2001-09       Impact factor: 2.850

6.  Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.

Authors:  A Wald; J Zeh; S Selke; T Warren; A J Ryncarz; R Ashley; J N Krieger; L Corey
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

7.  Performance of the focus and Kalon enzyme-linked immunosorbent assays for antibodies to herpes simplex virus type 2 glycoprotein G in culture-documented cases of genital herpes.

Authors:  Rhoda Ashley Morrow; David Friedrich; Elizabeth Krantz
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

8.  Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus.

Authors:  David M Koelle; Zhi Liu; Christopher M McClurkan; Max S Topp; Stanley R Riddell; Eric G Pamer; Andrew S Johnson; Anna Wald; Lawrence Corey
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 9.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

10.  Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants.

Authors:  W Chen; J W Yewdell; R L Levine; J R Bennink
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  58 in total

Review 1.  Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.

Authors:  K J Laing; L Dong; J Sidney; A Sette; D M Koelle
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

2.  Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Mina Kalantari; Payam Falatoonzadeh; Sookhee Chun; Chang Hyun Lim; Philip L Felgner; D Huw Davies; Lbachir BenMohamed
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling.

Authors:  Mina Kalantari-Dehaghi; Sookhee Chun; Aziz Alami Chentoufi; Jozelyn Pablo; Li Liang; Gargi Dasgupta; Douglas M Molina; Algis Jasinskas; Rie Nakajima-Sasaki; Jiin Felgner; Gary Hermanson; Lbachir BenMohamed; Philip L Felgner; D Huw Davies
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

Review 4.  The two faces of heterologous immunity: protection or immunopathology.

Authors:  Shalini Sharma; Paul G Thomas
Journal:  J Leukoc Biol       Date:  2013-11-08       Impact factor: 4.962

5.  Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.

Authors:  David J Davido; Eleain M Tu; Hong Wang; Maria Korom; Andreu Gazquez Casals; P Jahnu Reddy; Heba H Mostafa; Benjamin Combs; Steve D Haenchen; Lynda A Morrison
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

6.  A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.

Authors:  Sita Awasthi; Gregory G Mahairas; Carolyn E Shaw; Meei-Li Huang; David M Koelle; Christine Posavad; Lawrence Corey; Harvey M Friedman
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

7.  Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2.

Authors:  Christine M Posavad; Amalia S Magaret; Lin Zhao; Dawn E Mueller; Anna Wald; Lawrence Corey
Journal:  Vaccine       Date:  2011-07-27       Impact factor: 3.641

Review 8.  The challenge of developing a herpes simplex virus 2 vaccine.

Authors:  Lesia K Dropulic; Jeffrey I Cohen
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

9.  Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects.

Authors:  David M Koelle; Amalia Magaret; Christopher L McClurkan; Michael L Remington; Terri Warren; Florentina Teofilovici; Anna Wald
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

Review 10.  New concepts in herpes simplex virus vaccine development: notes from the battlefield.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Anthony B Nesburn; Steven L Wechsler; Lbachir BenMohamed
Journal:  Expert Rev Vaccines       Date:  2009-08       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.